Su1798 UPADACITINIB TREATMENT IS ASSOCIATED WITH IMPROVED CLINICAL AND QUALITY OF LIFE OUTCOMES IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE U-ENDURE LONG-TERM EXTENSION
David T. Rubin(University of California System), Peter Bossuyt(Imelda Hospital), Yoichi Kakuta(The University of Osaka), Julián Panés(Hospital Clínic de Barcelona), Elena Dubcenco(AbbVie (United States)), Samuel Anyanwu, Feng Tian(Sun Yat-sen University), Édouard Louis(Centre Hospitalier Universitaire de Liège), Benjamin Duncan(AbbVie (United States)), Astrid Rausch, Ana P. Lacerda(AbbVie (United States)), Tao Wang(Yunnan University of Traditional Chinese Medicine), Sharanya Ford(AbbVie (United States)), Namita Joshi, Luc Biedermann(University of Zurich)
Cited by 0
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
ACG Clinical Guideline: Ulcerative Colitis in Adults
|The American Journal of Gastroenterology|2019|1.6k